Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Diabetes (Glucometers, Glucose Monitoring, Continuous Glucose Monitoring [CGM] Companies)

OrSense

Attachments

*Architects: Blood Processing, Blood Pumps, Diagnostics, Hemorrhage, Bleeding, Hemostatis, Transfusion, Intravenous (IV) Management
*Architects: Diabetes (Glucometers, Glucose Monitoring, Continuous Glucose Monitoring [CGM] Companies)
*Architects: Laboratory Equipment, Information Systems & Services, Biotechnology, Biology, BioChemistry and Biomanufacturing, Specimens, & Cell Manufacturing, Good Manufacturing Practice (GMP) Software, Supplies & Blood Systems
*Architects: Medical Device_Diagnostics, Critical Care, BioSensors, ElectroPhysiological, EHR, Vital Signs Monitoring _ ICU Companies
*Industry: Israel
Venture Capital: Series C

Israel's OrSense announced this morning the closing of a $18 million financing round led by Israel Healthcare Ventures. Other participants in the financing included STAR Ventures and Lewis Trust Private Equity division (2011)
It also has received CE approval for the first non-invasive spot and continuous monitor of hemoglobin for anemia screening and hemorrhage detection applications.
OrSense closes $18M in financing (2011)
OrSense customers include blood donation facilities, hospital departments, public screening program and outpatient facilities.
OrSense received FDA clearance for its non-invasive multi parameter monitor for continuous and spot measurement of normal and low signal oximetry.
OrSense's CEO Lior Ma'ayan
OrSense's devices have been tested on 8000 subjects, in over 40 clinical trials at more than 20 sites worldwide.
OrSense's products target non-invasive monitoring of blood glucose in the hospital and for home use (2011)
Series D $18M by OnBioVC
The company's products are based on its proprietary optical technology, Occlusion Spectroscopy, which eliminates the need for needle-stick blood tests, and overcomes key obstacles of competing approaches.